ADL Amdl,

TUSTIN, Calif., May 22 /PRNewswire-FirstCall/ -- AMDL, Inc. (AMEX:ADL), (http://www.amdl.com/ ), a world leader in specialty pharmaceuticals with operations in Shenzhen, Jiangxi and Jilin, China, announced today that it has made available the AMDL executive management comments from its Q1 2008 financial results conference call. The document can be accessed via AMDL's corporate website at http://www.amdl.com/. Click on "Investor Relations," then "Recent News." The posted conference call script outlines prepared remarks AMDL's executive management made covering the Company's financial results for the first quarter of FY2008 and the subsequent question and answers from shareholders. Highlighted comments from AMDL's CEO Gary Dreher included: -- We have responded to the U.S. FDA regarding requests for information on our DR-70(TM) cancer test within the time period required; -- AMDL's executive management team is committed to increasing shareholder communications, including formally issuing corporate guidance; -- We are focused on growing annual sales at a minimum rate of 100 percent over the next three years. -- 2007 sales were $15 million and we are on track to at least doubling sales in 2008; -- AMDL will leverage its land holdings in China (estimated to be worth between $15-$21 million) to gain a new credit facility in place by Q3, 2008. -- We plan to finance continued growth with debt and credit lines. We do not plan to pursue the same type of 25 percent discounted equity funding as we've done in previous rounds; -- AMDL's anti-aging Goodnak product line is enjoying high growth demand and we anticipate it will be exported to the US and Europe in the future; -- AMDL's head of R&D Dr. Andrea Small-Howard has concluded that the HPV Test Kit licensed by the Company for distribution in China, Hong Kong, Taiwan, Singapore, Malaysia, Thailand, Cambodia and Vietnam has numerous advantages over other test kits for HPV and can become a major product for the Company. About AMDL: AMDL, Inc. is a global specialty pharmaceutical company. The company is headquartered in Tustin, California with operations in Shenzhen, Jiangxi, and Jilin, China. Along with its subsidiary Jade Pharmaceutical Inc. (JPI), AMDL is devoted to the research, development, manufacture, and marketing of diagnostic, pharmaceutical, nutritional supplement, and cosmetic products currently in China. The company employs approximately 320 people in the U.S. and China. More information about AMDL and its products can be obtained at http://www.amdl.com/ . About Jade Pharmaceutical: JPI has access to the fastest growing pharmaceutical and consumer market in the world: China. AMDL, through its subsidiaries, Jade currently manufactures large volume injection fluids, tablets and other related products, holding licenses for 133 products. It also manufactures 107 generic, over the counter and supplemental pharmaceutical products under certified Chinese Good Manufacturing Practice (CGMP) standards. IR Contact: Mr. Paul Knopick Direct: 949.707.5365 Voicemail: 714.505.4460 DATASOURCE: AMDL, Inc. CONTACT: Mr. Paul Knopick, +1-949-707-5365, Voicemail, +1-714-505-4460, for AMDL, Inc. Web site: http://www.amdl.com/

Copyright